Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence,mortality, survival,staging, and attribution to risk factors

China faces a disproportionate cancer burden to the population size and is undergoing a transition in the cancer spectrum. We extracted data in five aspects of cancer incidence, mortality, survival, staging distributions, and attribution to risk factors in China, the USA and worldwide from open-source databases. We conducted a comprehensive secondary analysis of cancer profiles in China in the above aspects,and compared cancer statistics between China and the USA. A total of 4,546,400 new cancer...     

Information for authors

Science in China Series C: Life Sciences, an academic journal cosponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China, and published by Science in China Press and Springer, is committed to publishing high-quality, original results in both basic and applied research. Science in China Series C: Life Sciences is published bimonthly in both print and electronic forms.     

蟦科昆虫地理分布研究初探

In the present paper,the origin of the fa-mily Perlidae and the distribution characters of the tribe and the subfamily were summarized and analyzed.Based on the distribution of the genera in the world,the eight distribution types of the genera were divided.In addition,the distribution characters of the Perlidae in China were also probed preliminarily.So far two subfamilies,four tribe and twenty genera have been found in China.Ten of them,of which three genera are endemic to China,are the Oriental genera;one Palaearctic genus;three Oriental-Palaearctic genera;one Oriental-Nearctic genus;four Oriental-Palaearctic-Nearctic genera and one Oriental-Palaearctic-Nearctic-Afrotropical genus.Moreover,the main distribution character of Chinese Perlidae is that most of the species distribute Central China region,South China region and Southwest China region.The Central China region centralizes the distribution and the break of the perlid species,and made the dispersal for the others regions.     

Glacial Refugia of Ginkgo biloba and Human Impact on Its Genetic Diversity： Evidence from Chloroplast DNA

Variations in the trnK region of chloroplast DNA were investigated in the present study using polymerase chain reactionrestriction fragment length polymorphism to detect the genetic structure and to infer the possible glacial refugia of Ginkgo biloba L. in China. In total, 220 individuals from 12 populations in China and three populations outside China were analyzed, representing the largest number of populations studied by molecular markers to date. Nineteen haplotypes were produced and haplotype A was found in all populations. Populations in south-western China, including WC, JF, PX, and SP, contained 14 of the 19 haplotypes and their genetic diversity ranged from 0.771 4 to 0.867 6. The TM population from China also showed a high genetic diversity （H = 0.848 5）. Most of the genetic variation existed within populations and the differentiation among populations was low （GsT = 0.2）. According to haplotype distribution and the historical record, we suggest that populations of G. biloba have been subjected to extensive human impact, which has compounded our attempt to infer glacial refugia for Ginkgo. Nevertheless, the present results suggest that the center of genetic diversity of Ginkgo is mainly in south-western China and in situ conservation is needed to protect and preserve the genetic resources.     

Information for authors

Science in China Series C: Life Sciences, an academic journal cosponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China, and published by Science in China Press, is committed to publishing high-quality, original results in both basic and applied research. Science in China Series C: Life Sciences is published in both print and electronic forms. It is indexed by Science Citation Index.     

SCIENCE IN CHINA (SCIENTIA SINICA)

Aims and ScopeScience in China is a comprehensive academic journal of natural sciences sponsored by the Chinese Academy of Sci-ences and the National Natural Science Foundation of China.The primary purpose is to provide regular,rapid and au-thoritative reviews of current important developments in scientific research in China for scientific workers in China andother countries.The contents are selected by an extensive editorial committee which is composed of the most highly     

Tyroserleutide tripeptide affects calcium homeostasis of human hepatocarcinoma BEL-7402 cells

Copyright by Science in China Press 2005 Primary hepatocarcinoma is one of the most fre-quent digestive-tract cancers, particularly in China. The incidence and death rate of primary hepatocarci-noma in China is the highest in the world, with about 1100 thousands people dying from primary hepatocar-cinoma per year[1]. Although the chemotherapeutic agents are the main therapeutic approach for hepato- carcinoma, they are relatively ineffective and result in many toxic and side effects. Accordin…     

Profile of Dr. Shougong Zhang

正Dr. Shougong Zhang received his bachelor’s degree in agriculture (forestry) from Anhui Agricultural College, Hefei, China, in January 1982, and obtained his Ph.D. degree in agriculture (forest management) from Beijing Forestry University, Beijing, China, in 1990. From 1982 to 1986, he taught silviculture and forest mensuration in Anhui Agricultural University. From 1990 to 1997, he worked in the Research Institute of Forestry of the Chinese Academy of Forestry (CAF), Beijing, China, and served as the Deputy Director and then the Director of the Institute. He served as the Vice President of CAF in 1997, then the Executive Vice President in 2002, and has been the President since 2007.     

Professor Haowen Xu:The founder of exercise biochemistry in China

Professor Haowen Xu(许豪文,1935-2004) was a famous sports scientist and the founder of Exercise Biochemistry in China (Fig.1).He dedicated his life to the study of sports science and made tremendous contributions to the formation and growth of the field of Exercise Biochemistry in China.He was the first to use theories of exercise biochemistry and sports medicine to guide athletes' training and competition in China (Yu,2006).     

Information for authors

Science in China Series C: Life Sciences, an academic journal cosponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China, and published by Science in China Press and Springer, is committed to publishing high-quality, original results in both basic and applied research.     

Information for authors

Science in China Series C:Life Sciences,an academic jour-nal cosponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China,and pub-lished by Science in China Press and Springer,is committed to publishing high-quality,original results in both basic and applied research.     

Information for authors

Science in China Series C:Life Sciences,an academic journal cosponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China,and published by Science in China Press and Springer,is committed to publishing high-quality,original results in both basic and applied research.Science in China Series C:Life Sciences is published monthly     

新起点，新态势 —— 《中国科学：生命科学》2010年述评

The year 2010 marks the sixtieth anniversary for the publication of Science in China series journals,and meanwhile the Science in China Series C: Life Sciences took a new name as Science China Life Sciences(SCLS in short).Simultaneously,it has been reformed to make a new start for this journal in its long history.The journal has appeared with a new face to the readers and authors in both the novel publishing style and the highly qualified articles.An extensive review was given to the journal’s specific progress in the year 2010 by highlighting some of the representative publications.     

Witnessing the advance of science and technology in life sciences in the new era

正Since the launch in 1950,Science China Series and Science Bulletin have published numerous significant scientific achievements,witnessing the development of science and technology in China and serving as a bridge connecting Chinese scientists with their counterparts in the international scientific community.     

Care of HIV-infected patients in China

Compared with high infection areas of the world, the total HIV infection rate in China is relatively low. Nonetheless, because of China＇s vast territory and large population, the potential infection risk must be taken seriously. In the next few years, needle sharing among injection drug users will remain the most common route of transmission for the HIV/AIDS epidemic in China. Unprotected sex is gradually becoming a major route of transmission. China began to implement HAART in 1999 according to international standards. Prior to 2003, there were only about 150 HIV/AIDS patients were treated with HAART in some clinical trials and about 100 HIV/AIDS patients were treated by private sources. Results of those treatments are the scientific basis for development of the therapeutic strategies in China. In March of 2003, the Chinese government initiated China CARES program. In November of 2003, the Chinese Ministry of Health announced a national policy of free ARV treatment to all HIV＋ Chinese citizens who were in poverty and required ARV therapy. There are total of 19,456 HIV/AIDS patients received free ARV drugs to date in 159 regions and 441 towns. Current challenges are how to follow-up and evaluate those patients in the clinical settings. The longer the therapy is postponed, the more side effects and the higher probability of drug resistance are going to occur. It remains unclear, therefore, when HAART regimen should be started in the HIV/AIDS population in China.     

Care of HIV-infected patients in China

Compared with high infection areas of the world, the total HIV infection rate in China is relatively low. Nonetheless,because of China‘s vast territory and large population, the potential infection risk must be taken seriously. In the next few years, needle sharing among injection drug users will remain the most common route of transmission for the HIV/AIDS epidemic in China. Unprotected sex is gradually becoming a major route of transmission. China began to implement HAART in 1999 according to international standards. Prior to 2003, there were only about 150 HIV/AIDS patients were treated with HAART in some clinical trials and about 100 HIV/AIDS patients were treated by private sources.Results of those treatments are the scientific basis for development of the therapeutic strategies in China. In March of 2003, the Chinese government initiated China CARES program. In November of 2003, the Chinese Ministry of Health announced a national policy of free ARV treatment to all HIV Chinese citizens who were in poverty and required ARV therapy. There are total of 19,456 HIV/AIDS patients received free ARV drugs to date in 159 regions and 441 towns.Current challenges are how to follow-up and evaluate those patients in the clinical settings. The longer the therapy is postponed, the more side effects and the higher probability of drug resistance are going to occur. It remains unclear,therefore, when HAART regimen should be started in the HIV/AIDS population in China.     

Current Status and Future Strategies for Development of Transgenic Plants in China

In this review,the author summarized the current status,challenges,and strategies in China in the development oftransgenic plants and its commercialization,Based on sets of successful examples and data achieved from execution ofthe National Special Project for Transgenic Plant Research and Commercialization in the last five years,the priorities andkey directions were put forward for the future development of transgenic plants in China.     

Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China

T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the world including in China, have been trying to harness the power of T cells against tumors for decades. Recently, the biosynthetic chimeric antigen receptor engineered T cell(CAR-T) strategy was developed and exhibited encouraging clinical efficacy, especially in hematological malignancies. Chimeric antigen receptor research reports began in 2009 in China according to our Pub Med search results. Clinical trials have been ongoing in China since 2013 according to the trial registrations on clinicaltrials.gov.. After years of assiduous efforts, research and clinical scientists in China have made their own achievements in the CAR-T therapy field. In this review, we aim to highlight CAR-T research and clinical trials in China, to provide an informative reference for colleagues in the field.     

SCIENCE IN CHINA (SCIENTIA SINICA)

Science in China is a comprehensive academic journal of natural sciences sponsored by the Chinese Academy ofSciences. The primary purpose is to provide regular, rapid and authoritative reviews of current importantdevelopments in scientific research in China for scientific workers in China and other countries. The contents areselected by an extensive editorial committee which is composed of the most highly esteemed scientists in China